could be trading lower today on an FDA database update that included am Elevidys patient death, which occurred in November in a patient who experienced muscle spasms and mylagia.
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
Despite mixed results using gene therapies to treat Duchenne muscular dystrophy, drug developers are pushing ahead with the ...
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...
Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...
Crossover-treated patients who received a placebo in Part 1, crossed over at 52 weeks and were treated with Elevidys in Part 2 improved 2.34 points from baseline compared to matched external ...
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that included am ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback